Dominic B. Dwyer

2 months ago | nature.com | Nora Penzel |Jean Addington |Celso Arango |Sylvain Bouix |Dylan Campbell |Eduardo Castro | +20 more

AbstractThe Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. The assessments include domains similar to those acquired in previous CHR studies along with novel domains that are collected longitudinally across a period of 2 years.

Apr 24, 2024 | nature.com | Dominic B. Dwyer |Sergi Papiol |Fabian Streit |Marcella Rietschel |Bertram Müller-Myhsok |Peter Falkai | +4 more

AbstractThe response variability to repetitive transcranial magnetic stimulation (rTMS) challenges the effective use of this treatment option in patients with schizophrenia. This variability may be deciphered by leveraging predictive information in structural MRI, clinical, sociodemographic, and genetic data using artificial intelligence. We developed and cross-validated rTMS response prediction models in patients with schizophrenia drawn from the multisite RESIS trial.